342 related articles for article (PubMed ID: 33594603)
1. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
Gao A; Pan X; Yang X; Lin Z
Invest New Drugs; 2021 Aug; 39(4):1132-1138. PubMed ID: 33594603
[TBL] [Abstract][Full Text] [Related]
2. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
[TBL] [Abstract][Full Text] [Related]
5. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.
Wu T; Tang C; Tao R; Yong X; Jiang Q; Feng C
Front Immunol; 2021; 12():693881. PubMed ID: 34552581
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of
Togo M; Yokobori T; Shimizu K; Handa T; Kaira K; Sano T; Tsukagoshi M; Higuchi T; Yokoo S; Shirabe K; Oyama T
Br J Cancer; 2020 May; 122(11):1686-1694. PubMed ID: 32238919
[TBL] [Abstract][Full Text] [Related]
9. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
[TBL] [Abstract][Full Text] [Related]
10. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.
Le Meitour Y; Foy JP; Guinand M; Michon L; Karabajakian A; Fayette J; Saintigny P; Mahtouk K
Oral Oncol; 2024 Feb; 149():106680. PubMed ID: 38218022
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
[TBL] [Abstract][Full Text] [Related]
12. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
[TBL] [Abstract][Full Text] [Related]
13. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
Foy JP; Bertolus C; Michallet MC; Deneuve S; Incitti R; Bendriss-Vermare N; Albaret MA; Ortiz-Cuaran S; Thomas E; Colombe A; Py C; Gadot N; Michot JP; Fayette J; Viari A; Van den Eynde B; Goudot P; Devouassoux-Shisheboran M; Puisieux A; Caux C; Zrounba P; Lantuejoul S; Saintigny P
Ann Oncol; 2017 Aug; 28(8):1934-1941. PubMed ID: 28460011
[TBL] [Abstract][Full Text] [Related]
14. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
PeerJ; 2023; 11():e15922. PubMed ID: 37663280
[TBL] [Abstract][Full Text] [Related]
15. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
Huang S; Xiong C; Tan K
Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
[TBL] [Abstract][Full Text] [Related]
17. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma.
Su NW; Dai SH; Hsu K; Chang KM; Ko CC; Kao CW; Chang YF; Chen CG
Cancer Immunol Immunother; 2024 Jan; 73(1):3. PubMed ID: 38175307
[TBL] [Abstract][Full Text] [Related]
18. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
19. [The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma].
Song P; Yan X; Jiang Y; Ye Y; Wang J; Han P
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Apr; 36(4):315-320. PubMed ID: 35511629
[No Abstract] [Full Text] [Related]
20. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
Monteiro de Oliveira Novaes JA; Hirz T; Guijarro I; Nilsson M; Pisegna MA; Poteete A; Barsoumian HB; Fradette JJ; Chen LN; Gibbons DL; Tian X; Wang J; Myers JN; McArthur MJ; Bell D; William WN; Heymach JV
Cancer Prev Res (Phila); 2021 Mar; 14(3):313-324. PubMed ID: 33277316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]